TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02189291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate catheter removal
Description: The indwelling catheter will be removed prior to exiting the operating room.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post op day 1 catheter removal
Description: For patients assigned to catheter removal on post operative day one, which is the standard of care at this point.
Study: NCT01827462

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent, inactivated influenza vaccine (TIV)
Description: Licensed Seasonal Influenza Vaccine TIV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent, inactivated influenza vaccine (TIV)
Description: Licensed Seasonal Influenza Vaccine TIV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent, inactivated influenza vaccine (TIV)
Description: Licensed Seasonal Influenza Vaccine TIV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent, inactivated influenza vaccine (IIV4)
Description: Licensed Seasonal Influenza Vaccine IIV4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
Description: Licensed Seasonal High-Dose Influenza Vaccine TIV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
Description: Licensed Seasonal High-Dose Influenza Vaccine TIV
Study: NCT01738516

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electroencephalography
Description: Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electroencephalography and additional experimental tasks
Description: Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
Study: NCT02185443

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: * 60Gy in 3 fractions (20Gy/fraction) over 14 days~* 60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above
Study: NCT03986905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Nasal Gel
Description: All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine Nasal Gel
Description: All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo nasal gel + placebo patch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo nasal gel + placebo patch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo nasal gel + placebo patch
Study: NCT02873806

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Implantation of two iStent inject micro-bypass stents
Description: - Implantation of two trabecular micro-bypass stents (iStent inject) in a standalone procedure (i.e., without cataract surgery).

Intervention type: DRUG
Group type: OTHER
Intervention: Topical travoprost
Description: - Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.

Intervention type: DEVICE
Group type: OTHER
Intervention: Two iStent inject micro-bypass stents
Description: - Two trabecular micro-bypass stents (iStent inject) implanted in a standalone procedure.

Intervention type: DRUG
Group type: OTHER
Intervention: Tobramycin
Description: Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) .
Study: NCT03587441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine Methylsulfate
Description: 20 µg Neostigmine Methylsulfate intrathecal in 0.2 ml of Dextrose 5% solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5% in water
Description: intrathecal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5% in water
Description: intrathecal
Study: NCT04348032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd
Description: Patients receive PLD and apatinib at the same time. The dose of intravenous chemotherapy drug is calculated according to the body surface area, and the dose of oral drug apatinib is 250mg qd. Dose suspension and dose reduction are allowed only when patients have serious adverse reactions. The intravenous chemotherapy drug PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%), and the oral drug apatinib dose is only allowed to be reduced once (250mg gravity QD changed to 250mg gravity Qod). Otherwise the patients will drop out of the study.
Study: NCT02873806

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):~* Week 1: 1 drop four (4) times per day in the study eye~* Week 2: 1 drop three (3) times per day in the study eye~* Week 3: 1 drop two (2) times per day in the study eye~* Week 4: 1 drop one (1) time per day in the study eye
Study: NCT04217174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Personal Health Guide
Description: My Personal Health Guide is a theory-based mobile phone app that uses an Avatar as a personal health guide to increase patient knowledge of HIV disease and its complications and rationale for healthy behavior, increase self-efficacy and motivate participants to improve retention in care and medication adherence, and explain and illustrate behavioral skills related to retention in care, and adherence, with a result of improved behavior that leads to personal and population benefits through viral suppression and decreased risk of transmission, respectively. The relational aspect of the Avatar may be a powerful supplement to clinical care. The Avatar can encourage healthy behavior, acknowledge stigma and speak with empathy, audibly teach persons with low literacy, employ credible culturally appropriate phrasing, and invite the user to hear advice and motivational stories of other HIV-positive people and caregivers.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: My Personal Food Guide
Description: My Personal Food Guide is a mobile phone app that contains a talking realistic avatar who teaches about food safety, sugar content in selected foods, and some other food related information. The avatar motivates safe food behavior in order reduce the likelihood of food poisoning and promotes a healthy diet.
Study: NCT01100931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM155
Description: Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m\^2, dose level 2:5 mg/m\^2 , dose level 3:6 mg/m\^2, dose level 4:8 mg/m\^2, dose level 5:10 mg/m\^2 (MTD), dose level 6:12 mg/m\^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m\^2 (MTD)intravenous infusion over 72 hours every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under curve (AUC) of 6 intravenous on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m\^2 intravenous on day 1
Study: NCT00201682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 25 mg SQ twice weekly weeks 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: (375 mg/m2) Using Stepped-Up Dosing Thrice Weekly, weeks 2-5
Study: NCT01694849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 120mg
Study: NCT01814501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study: NCT01839552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate Nasal Spray (FCNS)
Study: NCT02775344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three dimension laparoscopy
Description: Surgery will be performed either with three dimension laparoscopy or two dimension laparoscopy.
Study: NCT04339400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105
Description: TQ05105 is a JAK2 inhibitor.
Study: NCT01694849

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03695471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT00577382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study: NCT03303144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: ferric pyrophosphate citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: ferric pyrophosphate citrate
Study: NCT03225417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules. Phase I: Starting dose of Ixazomib: 3.0 or 4.0 mg by day +1, +8 and +15. Phase II: Starting Dose of Ixazomib: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Tacrolimus at dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus at dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.

Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: Sirolimus oral solution. Standing 6 mg orally on day -5 and continued 4mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus oral solution. Standing 6 mg orally on day -5 and continued 4mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.

Intervention type: DRUG
Group type: OTHER
Intervention: Any prophylaxis for GVHD
Description: Except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Any prophylaxis for GVHD
Description: Except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
Study: NCT04092140

Intervention type: DEVICE
Intervention: ultrasound
Description: easy new non invasive tool

Intervention type: DEVICE
Intervention: ultrasound
Description: easy new non invasive tool
Study: NCT03595956

Intervention type: OTHER
Intervention: Medical gender affirmation
Description: The intervention to be evaluated is medical gender affirmation delivered in primary care (medical gender affirmation: hormones and/or surgery vs none).
Study: NCT00033397

Intervention type: PROCEDURE
Intervention: biopsy

Intervention type: PROCEDURE
Intervention: magnetic resonance imaging

Intervention type: PROCEDURE
Intervention: radiomammography

Intervention type: PROCEDURE
Intervention: ultrasound imaging

Intervention type: RADIATION
Intervention: gadopentetate dimeglumine

Intervention type: DRUG
Intervention: chemotherapy
Study: NCT02692859

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib conjugate vaccine
Description: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose
Study: NCT02502188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03303144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: ferric pyrophosphate citrate
Study: NCT03730064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Description: Experimental medication with N-acetyl cysteine (NAC) for six weeks
Study: NCT01655368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapeutic STEM modules
Description: psychoeducational and psychotherapeutical group intervention. 8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module for schizophrenia or depression)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interventional control of normal psychoeducational treatment
Description: 11 sessions + 1 booster session of psychoeducation (for schizophrenia or depression)
Study: NCT04348032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLD 40mg/m2 ivgtt q4w
Description: The dose of intravenous chemotherapy drug is calculated according to the body surface area. When patients have serious adverse reactions, dose suspension and dose reduction are allowed. The PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%).
Study: NCT02434419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PENS
Description: The participants underwent one 30-min session every week for 12 consecutive weeks. PENS was delivered by a needle electrode inserted in the medioclavicular line, 2 cm below the clavicle at a 90° angle towards the skin at a depth of approximately 1 cm. PENS was undertaken at frequency of 20 Hz at the highest amplify (0-20 mA) without causing pain. PENS was delivered simultaneously in both pectoral muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific training
Description: Patients underwent specific training exercises to improve pectoral fitness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specific training
Description: Patients underwent specific training exercises to improve pectoral fitness.
Study: NCT01623375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).
Study: NCT03158441

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast MRI
Description: comparison of DTI to dynamic MRI
Study: NCT02028052

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ROSE
Description: The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.
Study: NCT04693286

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: novel oral polio type 2 vaccine (nOPV2)
Description: • nOPV2 (C1) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells (S2/cre5/S15domV/rec1/hifi3). Placebo contain sucrose in buffer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains no active ingradients, only sucrose in buffer
Study: NCT04346836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-intensity, general-fitness exercises
Description: 24 session of low-intensity, general-fitness exercises (12 weeks, twice a week)~A single session of exercise lasted 40 minutes and consisted of 42 low-intensity, general-fitness exercises. Perception of effort was monitored using the Borg 6-20 rating the perceived exertion (RPE).~Thirty-three exercises were done sitting down, seven standing, and two in the hand-and-knees position. The exercises were classified as either aerobic, musculo-articular, or stabilising. The aerobic portion served as a general warm-up for the subsequent exercises, and the musculo-articular section focused on strengthening muscles and enhancing the mobility of joints in the upper limbs, the lower limbs and the torso. Stabilising exercises were designed to improve the stability of the body and to augment spatio-visual coordination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-intensity, general-fitness exercises
Description: 24 session of low-intensity, general-fitness exercises (12 weeks, twice a week)~A single session of exercise lasted 40 minutes and consisted of 42 low-intensity, general-fitness exercises. Perception of effort was monitored using the Borg 6-20 rating the perceived exertion (RPE).~Thirty-three exercises were done sitting down, seven standing, and two in the hand-and-knees position. The exercises were classified as either aerobic, musculo-articular, or stabilising. The aerobic portion served as a general warm-up for the subsequent exercises, and the musculo-articular section focused on strengthening muscles and enhancing the mobility of joints in the upper limbs, the lower limbs and the torso. Stabilising exercises were designed to improve the stability of the body and to augment spatio-visual coordination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: A psychoeducation provided by psychotherapist. Twenty minutes of psychoeducation, which contained mini lectures about mental well-being, psychohygiene and healthy dietary habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: A psychoeducation provided by psychotherapist. Twenty minutes of psychoeducation, which contained mini lectures about mental well-being, psychohygiene and healthy dietary habits.
Study: NCT03650140

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart cherry extract 60 mL
Description: Subjects will receive a single 60 mL oral dose of tart cherry extract.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart cherry extract 60 mL
Description: Subjects will receive a single 60 mL oral dose of tart cherry extract.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart cherry extract 120 mL
Description: Subjects will receive a single 120 mL oral dose of tart cherry extract.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart cherry extract 120 mL
Description: Subjects will receive a single 120 mL oral dose of tart cherry extract.
Study: NCT01350128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 MDI
Description: PT001 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 MDI
Description: PT001 MDI administered as two puffs BID for 7 days
Study: NCT02028052

Intervention type: DEVICE
Group type: OTHER
Intervention: 22 gauge Vizishot needles

Intervention type: DEVICE
Group type: OTHER
Intervention: 22 gauge Vizishot needles
Study: NCT02567721

Intervention type: OTHER
Intervention: Vaccine safety surveillance
Description: Extraction of routinely collected primary care data from nine GP practices and an active surveillance approach in 3 of the 9 GP practices, by using an existing card-based ADR reporting system (MHRA Yellow Card), to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
Study: NCT00971100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
Study: NCT01258023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluad 1x
Description: 15 µg antigen/strain:~* A/California/07/2009 (H1N1) - like strain~* A/Perth/16/2009 (H3N2) - like strain~* B/Brisbane/60/2008- like strain MF59 adjuvant 9.75µg ai 0.5ml
Study: NCT02702180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim
Description: 300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim
Description: 300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim
Description: 300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nebulizer solution for inhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARI eFlow nebulizer system
Description: PARI eFlow nebulizer system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARI eFlow nebulizer system
Description: PARI eFlow nebulizer system

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PARI eFlow nebulizer system
Description: PARI eFlow nebulizer system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARI eFlow nebulizer system
Description: PARI eFlow nebulizer system
Study: NCT03877302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reflexology
Description: foot reflexology
Study: NCT03646474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic Acid infusion
Description: The tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Description: In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.